Comparative Pharmacology
Head-to-head clinical analysis: ICOTYDE versus STIOLTO RESPIMAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICOTYDE versus STIOLTO RESPIMAT.
ICOTYDE vs STIOLTO RESPIMAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ICOTYDE (trifluridine/tipiracil) is a combination of trifluridine, a thymidine-based nucleoside analog that incorporates into DNA and inhibits cell proliferation, and tipiracil, a thymidine phosphorylase inhibitor that increases the systemic exposure of trifluridine by inhibiting its degradation.
Dual bronchodilator: tiotropium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors at smooth muscle, causing bronchodilation; olodaterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, relaxing airway smooth muscle.
Intravenous: 1000 mg administered over 90 minutes on days 1 and 15 of a 28-day cycle.
2 inhalations (2.5 mcg tiotropium/2.5 mcg olodaterol per inhalation) once daily via Respimat inhaler.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged in renal impairment.
Tiotropium: 5-6 days (terminal). Olodaterol: 17-19 hours (terminal). Clinically, once-daily dosing maintains therapeutic levels.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing the remaining 30%.
Tiotropium: 14% renal unchanged, remainder as non-renally eliminated metabolites (biliary/fecal). Olodaterol: <1% renal unchanged, 84% fecal as metabolites, 16% renal as metabolites.
Category C
Category C
ICS/LABA Combination
LAMA/LABA Combination